SCHEMBL4820184

SCHEMBL4820184

O=C(Nc1cc2ccc(O)cc2oc1=O)c1cccnc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.61
ALDH1A1 P00352 5/20 0.57
KDM4E B2RXH2 4/20 0.57
POLB P06746 2/20 0.56
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
MAPT P10636 3/20 0.49
GAA P10253 2/20 0.49
GLA P06280 1/20 0.49
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
CA1 P00915 1/20 0.47
HPGD P15428 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAOB P27338 3/20 0.46
ACHE P22303 2/20 0.46
RXFP1 Q9HBX9 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
AKR1B10 O60218 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4820097 0.84 TP53 (0.70) TP53ALDH1A1KDM4EPOLBKMT2A
SCHEMBL4819065 0.79 TP53 (0.70) TP53ALDH1A1KDM4EPOLBKMT2A
SCHEMBL4815156 0.78 TP53 (0.68) TP53ALDH1A1KDM4EPOLBKMT2A
SCHEMBL4813586 0.76 MAPT (0.79) TP53ALDH1A1KDM4EPOLBKMT2A
SCHEMBL4819228 0.76 POLB (0.77) TP53ALDH1A1KDM4EPOLBKMT2A
SCHEMBL4819273 0.76 TP53 (1.00) TP53ALDH1A1KDM4EPOLBKMT2A
SCHEMBL4817800 0.76 TP53 (0.76) TP53ALDH1A1KDM4EPOLBKMT2A
SCHEMBL4818996 0.74 MAOB (0.74) TP53ALDH1A1KDM4EPOLBKMT2A
SCHEMBL4820362 0.73 TP53 (0.67) TP53ALDH1A1KDM4EPOLBKMT2A
SCHEMBL4821180 0.73 TP53 (0.79) TP53ALDH1A1KDM4EPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7411076-B2 such as 2-chloro-N-(7-hydroxy-2-oxo-2H-1-benzopyran-3-yl)benzamide, used for intensifying the effects of cancer therapy based on DNA injury; protein kinase inhibitors; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-08-12 US disclosed
US-20050054717-A1 Coumarin derivative INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054717-A1 Coumarin derivative ERCC2, ERCC4, DDB1 TP53 81/4885ALDH1A1 302/4885KDM4E 3979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.